Faruqi & Faruqi, LLP Supports Kyverna Investors Amid Allegations of Misconduct
Faruq & Faruqi, LLP Investigates Kyverna
Faruqi & Faruqi, LLP, a prominent national securities law firm, has announced an investigation into potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX). This investigation comes in light of allegations suggesting that the company, which had its initial public offering (IPO) on February 8, 2024, made misleading statements about its clinical trial results. Investors who have sustained losses exceeding $50,000 following this IPO are encouraged to reach out and discuss their legal options with securities litigation partner, Josh Wilson.
In their complaint, Faruqi & Faruqi states that the registration statement and prospectus for Kyverna's IPO failed to accurately report the status of ongoing clinical evaluations, particularly regarding the company’s KYV-101 treatment. It has been reported that while Kyverna hinted at patient
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.